- Product Partners
- Supplements Facts
- Scientific References
- Client Reviews
Build Better Bones with Plant Calcium – and Much More
Traditional calcium supplements do not actually help increase bone mineral density - at best they help bone health by slowing down the rate of bone loss. Some researchers attribute this to the fact that traditional calcium supplements are made from rocks (like limestone), not a food source the body is used to digesting, tolerating and using efficiently.
A new source of calcium from a marine plant branded as AlgaeCal® has changed this - it has been shown in multiple clinical studies to actually grow bone, not just slow bone loss. In addition, other studies have shown AlgaeCal® is safe when used as directed.
AlgaeCal® is USDA certified organic and harvested from a marine plant off the coastline of South America. It naturally provides calcium in a form that’s easy for your stomach to use - as well as numerous other minerals that support bone health, like magnesium.
Plus, AlgaeCal® has been shown to be effective using just 750mg a day - compared to most calcium supplements that require 1,000mg or more per day. TrueOsteo™ also contains the same 1,000 IU per day of vitamin D3 that complemented AlgaeCal® in the clinical studies.
TrueOsteo™ contains the clinically studied MeanQ7® vitamin K2. It’s highly recommended when taking a calcium supplement to also take vitamin K2 because vitamin K2 helps put calcium where you want it - in your bones, not your arteries.
In a recent clinical study, particpants taking 180mcg of MenaQ7® vitamin K2 daily (the same amount used in TrueOsteo™) for three years experienced significantly improved bone strength, bone mineral density and bone mineral content.
Emerging research has found a high cortisol level is a major culprit in bone loss -underscoring the need to keep your cortisol levels in a normal range. The patented ashwagandha extract Sensoril® has been shown to help maintain healthy cortisol levels.
AlgaeCal®: USDA Certified Organic Plant Calcium (and more!)
Studies involving calcium supplements often report an “increase in bone density”, but rarely is it an outright increase - but instead a “slower” rate of bone loss compared to a placebo group.
That’s what makes AlgaeCal® different. Not only is it from a marine plant and USDA certified organic, AlgaeCal® has been shown in clinical studies (when combined with vitamin D3) to actually increase bone density, and not just slow down the rate of bone loss.
As the name suggests, AlgaeCal® is harvested from the algas calcareas plant, which naturally grows in shallow ocean waters off the coast of South America. It’s made from a living plant - not an inorganic dense rock, which is the source of the calcium in most supplements.
One reason why AlgaeCal® works so well is because the plant sourced nutrients are in a “whole food state.” As a result, the calcium gets readily absorbed by your stomach.
This is especially important as you get older because your stomach produces less acid, and foods can become harder to digest - meaning fewer nutrients get absorbed by your body.
To demonstrate the ability of AlgaeCal® to be absorbed, a simulation of the human digestive tract was conducted at the highly respected scientific analysis institute, C.E.V.A., in France.
At C.E.V.A., the calcium absorption of AlgaeCal® was compared to some typical foods that are high in calcium content - like yogurt, pears, oranges and cauliflower.
The researchers were surprised that AlgaeCal® demonstrated higher calcium absorption than all of the foods tested. For example, 75% of the calcium in AlgaeCal® was absorbed -compared to only 43% of the calcium in yogurt.
Beyond its absorption profile, the second reason why AlgaeCal® works so well is because like other food, AlgaeCal® naturally contains many other beneficial minerals other than calcium.
And according to USDA researchers and other scientists, many of these are integral to building strong bones - minerals such as magnesium, silicon, strontium, manganese, vanadium, zinc, and boron. Together, they provide additional bone health support.
This was recently demonstrated by researchers from the Harvard Medical School and University of Connecticut. Their work was published in the journal, Molecular and Cellular Biochemistry.
In direct head-to-head tests, the scientists compared the bone-building effects of AlgaeCal® with the two top-selling calcium ingredients - which are the rock-based calcium carbonate and calcium citrate.
The results showed AlgaeCal® outperformed calcium carbonate and calcium citrate by 300% and 400%, respectively, on DNA synthesis - the ability of human cells called “osteo-blasts” to produce new bone building cells.
Similarly, AlgaeCal® was proven overwhelmingly superior in all other tests conducted by these scientists.
This study was significant because it was the first time that a calcium ingredient stood head and shoulders above the others when measuring its effect on stimulating bone cells.
In the various clinical studies, AlgaeCal® has been found to be well tolerated by users with no reported side effects. On top of that, a panel of 43 blood tests demonstrated no safety concerns.
What’s more, six different safety studies have been conducted in the United States and Europe, and demonstrate the safety of AlgaeCal®. These six studies have been combined into one manuscript which was published in the journal, Toxicology Mechanisms and Actions.
Finally, efficacy has been shown by taking only 750mg of calcium from AlgaeCal®, instead of the 1,200mg of “rock” calcium found in most supplements.
MenaQ7®: The Only Clincially Studied Vitamin K2 for Bone and Cardiovascular Health Benefits.
Recent research has shown vitamin K2 is a very important nutrient with its most important function being helping to keep calcium in your bones and out of your arteries.
Unfortunately, other work shows that as many as 97% of the Western population is deficient in vitamin K2 because we don’t get enough through diet alone.
This makes taking a vitamin K2 supplement a good idea. Vitamin K2 is typically available in supplements either as MK-4 or MK-7.
Vitamin K2 is technically known as a “menaquinone.” So when you see “MK”, it is just an abbreviation for menaquinone. And the number “4” or “7” refers to the length of the vitamin K2 molecule - or the number of menaquinones it contains.
However, you should also know that only vitamin K2 as MK-7 is made from a natural source. In the case of the MenaQ7® in TrueOsteo™, the vitamin K2 is made from chick peas (most other vitamin K2 ingredients come from soy).
Besides being synthetic, the problem with MK-4 is it disappears from the blood almost as quickly as it enters - because its half-life is only 1 to 2 hours. So you need to take extremely large doses multiple times a day - which can be really expensive and inconvenient. Plus, the large dose needed would be way above the recommended consumption level for vitamin K2.
That’s why we only use vitamin K2 as MK-7 - and the premier brand is MenaQ7®. In fact, MenaQ7® is the only vitamin K2 brand clinically studied and shown to deliver both bone and cardiovascular benefits.
In a recent clinical study, 240 post-menopausal women (average age 60 years old) took 180mcg of MenaQ7® or a placebo daily for three years.
The results showed that those taking MenaQ7® started to experience bone health benefits in the first year and these became much more magnified over the three year period. Specifically, supplementing with MenaQ7® led to significantly improved:
Each of these improvements is impressive and important to your bones, but most noticeable was the bone strength improvement.
Using a measure called the “Impact Strength Test”, it was determined by the researchers that the women taking MenaQ7® had barely any bone strength loss, while the placebo group decreased each year, suffering a 3.5% loss by the end of the study.
What’s more, TrueOsteo™ is made with the most advanced form known as MenaQ7® Crystals. This ingredient represents the most significant technological breakthrough in the new generation of vitamin K2. Here are some of the features of MenaQ7® Crystals:
In addition, MenaQ7® is suitable for vegans and vegetarians, free from gluten, dairy, soy, and other known allergens.
Sensoril®: Helps Protect Your Body (and Bones) From The Effects of Stress.
Like many substances in your body, when you have normal levels of cortisol it does some very good things. Some of these include helping to keeping blood sugar under control, improving memory and reducing your sensitivity to pain.
Cortisol gets released when your body encounters a stressful situation - hence why it’s called the “stress hormone.” And because we live in a stressful society, many people have elevated levels of cortisol - which over time can lead to negative health consequences.
Until recently, it was never understood how much cortisol negatively affects bone health. However, several recent research studies from Italy and the United States demonstrated that high levels of cortisol correlate directly to low levels of bone mineral density.
The exact reasons why cortisol causes bone loss isn’t entirely clear yet. However, preliminary evidence suggests cortisol: (i) interferes with calcium, magnesium and other mineral absorption in the intestines, (ii) inhibits osteoblast (bone building) activity and (iii) activates osteoclasts which causes bone to be resorbed (bones degrade faster).
To help promote normal cortisol levels, TrueOsteo™ includes an ashwaganda plant extract called Sensoril®.
Sensoril® was invented by Fulbright Scholar Dr. Shibnath Ghosal - and has been clinically shown to help keep cortisol in balance.
The ashwaganda plant used to make Sensoril® is known as an “adapatogen” - meaning it helps the body return to a balanced state. So if your cortisol levels are normal, Sensoril® doesn’t cause them to plummet to below normal. It’s there to help keep cortisol in balance.
The benefits of Sensoril® have been demonstrated in 11 clinical studies involving human beings. These include reducing stress, boosting energy, promoting joint health, improving mental acuity and concentration and supporting normal cardiovascular function.
Dietary Supplement / 120 capsules
Serving Size: 2 capsules
Servings per Container: 60
|Amount Per Serving (2 capsules)||Amount Per Day (4 capsules)|
|Amount||% Daily Value||Amount||% Daily Value|
|Vitamin D (as vitamin D3 cholecalciferol)||500 IU||125%||1,000 IU||250%|
|Vitamin K (as K2 menaquinone-7)(MenaQ7® chickpea extract)||90 mcg||113%||180 mcg||225%|
|Calcium (from AlgaeCal®)||360 mg||36%||720 mg||72%|
|Magnesium (from AlgaeCal®)||32 mg||8%||64 mg||16%|
|AlgaeCal® (Algas calcareas.sp)||1,285 mg||*||2,570 mg||*|
|Sensoril® (Withania somnifera)(ashwagandha root and leaf extract)||125 mg||*||250 mg||*|
|Boron (as boron chelate)||1 mg||*||2 mg||*|
* Daily value not established.
Other ingredients: gelatin, rice flour, vegetable magnesium stearate, silica and medium chain triglycerides.
Sensoril® is a registered trademark of Natreon, Inc. and is protected under U.S. Patent # 6,713,092 / AlgaeCal® is a registered trademark of AlgaeCal Distribution, Inc. / MenaQ7® is a trademark of NattoPharma, Norway; patented in the United States and Canada.
SUGGESTED USE: Take a total of four (4) capsules per day, preferably two (2) capsules in the morning and two (2) capsules in the evening.
TrueOsteo™ is made with a USDA certified organic plant sourced calcium and mineral complex called AlgaeCal®, along with other bone health supporting nutrients.†
Take TrueOsteo™ with a meal to optimize absorption.
Caution: TrueOsteo™ contains vitamin K2. If you are using blood-thinning medications, consult your healthcare provider before using TrueOsteo™.
Keep out of reach of children.
Store at 15-30° C (59-86° F).
Protect from heat, light and moisture.
Do not purchase if seal is broken.
†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
- Assembled in the USA
Manufactured for and Distributed by: NatureCity®
Boca Raton, FL 33487 www.naturecity.com
To re-order call toll free 1-800-593-2563
Michalek JE, Preuss HG, Croft HA, Keith PL, Keith SC, Dapilmoto M, Perricone NV, Leckie RB, Kaats GR. “Changes in total body bone mineral density following a common bone health plan with two versions of a unique bone health supplement: a comparative effectiveness research study.” Nutrition Journal. 2011 Apr 14;10:32.
Kaats GR, Preuss HG, Croft HA, Keith SC, Keith PL. “A comparative effectiveness study of bone density changes in women over 40 following three bone health plans containing variations of the same novel plant-sourced calcium.” International Journal of Medical Sciences. 2011 Mar 2;8(3):180-91.
Adluri RS, Zhan L, Bagchi M, Maulik N, Maulik G. “Comparative effects of a novel plant-based calcium supplement with two common calcium salts on proliferation and mineralization in human osteoblast cells.” Molecular and Cellular Biochemistry. 2010 Jul;340(1-2):73-80.
Marone PA, Yasmin T, Gupta RC, Bagchi M. “Safety and toxicological evaluation of AlgaeCal (AC), a novel plant-based calcium supplement.” Toxicology Mechanisms and Methods. 2010 Jul;20(6):334-44.
Centre d'Etude et de Valorisation des Algues (CEVA) “AlgaeCal biodisponibility test” 2007
Gaffney-Stomberg E, Lutz LJ, Rood JC, Cable SJ, Pasiakos SM, Young AJ, McClung JP. “Calcium and vitamin D supplementation maintains parathyroid hormone and improves bone density during initial military training: a randomized, double-blind, placebo controlled trial.” Bone. 2014 Nov;68:46-56.
Hong Q, Xu J, Xu S, Lian L, Zhang M, Ding C. “Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis.” Rheumatology (Oxford). 2014 Nov;53(11):1994-2001.
Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M. “Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis.” The American Journal of Clinical Nutrition. 2014 Sep;100(3):746-55.
Mager DR, Jackson ST, Hoffmann MR, Jindal K, Senior PA. "Vitamin D supplementation and bone health in adults with diabetic nephropathy: the protocol for a randomized controlled trial". BMC Endocr Disord. 2014 Aug 12;14:66.
Curtis EM, Moon RJ, Dennison EM, Harvey NC. “Prenatal calcium and vitamin D intake, and bone mass in later life.” Current Osteoporosis Reports. 2014 Jun;12(2):194-204.
Shuler FD, Schlierf T, Wingate M. Preventing falls with vitamin D.
West Virginia State Medical Association. 2014 May-Jun;110(3):10-2.
Ohta H, Uemura Y, Nakamura T, Fukunaga M, Ohashi Y, Hosoi T, Mori S, Sugimoto T, Itoi E, Orimo H, Shiraki M. “Adequate Serum 25-hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with a high risk for fracture.”Clinical Therapeutics. 2014 Feb 1;36(2):225-35.
Chlebowski RT, Pettinger M, Johnson KC, Wallace R, Womack C, Mossavar-Rahmani Y, Stefanick M, Wactawski-Wende J, Carbone L, Lu B, Eaton C, Walitt B, Kooperberg CL. “Calcium plus vitamin D supplementation and joint symptoms in postmenopausal women in the women's health initiative randomized trial.”
Journal of the Academy of Nutrition and Dietetics. 2013 Oct;113(10):1302-10.
Macdonald, H. M., Wood, A. D., Aucott, L. S., Black, A. J., Fraser, W. D., Mavroeidi, A., Reid, D. M., Secombes, K. R., Simpson, W. G. and Thies, F., “Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: A 1-year double-blind RCT in postmenopausal women.” 2013 J Bone Miner Res, 28: 2202–2213
Hermann, W, Kirsch SH, Kruse V, Eckert R, Gräber S, Geisel J, Obeid R. “One year B and D vitamins supplementation improves metabolic bone markers.” Clin Chem Lab Med. 2013 Mar 1;51(3):639-47.
McAlindon T, et al. “Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial.” The Journal of the American Medical Association. 2013 Jan 9;309(2):155-62.
Glover TL1, et al. “Vitamin D, race, and experimental pain sensitivity in older adults with knee osteoarthritis.” Arthritis & Rheumatology. 2012 Dec;64(12):3926-35.
Lauretani F, Frondini C, Davoli ML, Martini E, Pellicciotti F, Zagatti A, Giordano A, Zurlo A, Pioli G. “Vitamin D supplementation is required to normalize serum level of 25OH-vitamin D in older adults: an observational study of 974 hip fracture inpatients.” J Endocrinol Invest. 2012 Nov;35(10):921-4.
Bischoff-Ferrari, H.A., Willett, W.C., Orav, E.J., Lips, P., Meunier, P.J., Lyons, R.A. et al, “A pooled analysis of vitamin D dose requirements for fracture prevention.” N Engl J Med. Jul 5 2012;367:40–49.
Gallagher JC, Sai A, Templin T 2nd, Smith L. “Dose response to vitamin D supplementation in postmenopausal women: a randomized trial.” Ann Intern Med. 2012 Mar 20;156(6):425-37
Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. “Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.” Lancet. 2007 Aug 25;370(9588):657-66.
Broe KE, et al. “A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study.” Journal of the American Geriatrics Society. 2007 Feb;55(2):234-9.
Bischoff -Ferrari HA. “How to select the doses of vitamin D in the management of osteoporosis.” Osteoporos Int 2007;18: 401–07.
Jackson RD, LaCroix AZ, Gass M, et al. “Calcium plus vitamin D supplementation and the risk of fractures.” N Engl J Med 2006; 354: 669–83.
Ruohola JP, et al. “Association between serum 25(OH)D concentrations and bone stress fractures in Finnish young men.” Journal of Bone and Mineral Research. 2006 Sep;21(9):1483-8.
The RECORD Trial Group. “Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial.” Lancet 2005; 365: 1621–28.
Bischoff -Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. “Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials.” JAMA 2005; 293: 2257–64.
Avenell A, Gillespie W, Gillespie L, O’Connell D. “Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis.” Cochrane Database Syst Rev 2005; 3: CD000227
Boonen S, Lips P, Bouillon R, Bischoff -Ferrari HA, Vanderschueren D, Haentjens P. “Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative meta-analysis of randomized controlled trials.” J Clin Ednocrinol Metab 2007; 92: 1415–23.
Larsen E, Mosekilde L, Foldspang A. “Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study.” J Bone Miner Res 2004; 19: 370–78.
Bischoff-Ferrari HA, et al. “Effect of Vitamin D on falls: a meta-analysis.” The Journal of the American Medical Association. 2004 Apr 28;291(16):1999-2006.
Meier C, Woitge H, Witte K, Lemmer B, Seibel M. “Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.” J Bone Miner Res 2004; 19: 1221–30.
Chapuy M, Pamphile R, Paris E, et al. “Combined calcium and vitamin D3 supplementation in elderly women: confi rmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study.” Osteoporos Int 2002; 13: 257–64.
Porthouse J, Cockayne S, King C, et al. “Randomised controlled trial of supplementation with calcium and cholecalciferol (vitamin D3) for prevention of fractures in primary care.” BMJ 2005; 330: 1003–06.
Baeksgaard L, Andersen K, Hyldstrup L. “Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women.” Osteoporos Int 1998; 8: 255–60.
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. “Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.” N Engl J Med 1997; 337: 670–76.
McAlindon TE, et al. “Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study.” Annals of Internal Medicine. 1996 Sep 1;125(5):353-9.
MenaQ7® Vitamin K2
Knapen MH, Braam LA, Drummen NE, Bekers O, Hoeks AP, Vermeer C. “Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: double-blind randomised clinical trial.” Journal of Thrombosis and Haemostasis. 2015 Feb 19;113(5).
Theuwissen E, Magdeleyns EJ, Braam LA, Teunissen KJ, Knapen MH, Binnekamp IA, van Summeren MJ, Vermeer C: “Vitamin K status in healthy volunteers.” Food Funct 2014, 5:229-234.
Caluwe, R., Vandecasteele, S., Van Vlem, B., Vermeer, C., De Vriese, A.S. “Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study.” Nephrol. Dial. Transplant. 2014;29:1385–1390.
Kurnatowska L, Grzelak P, Kaczmarska, Masajtix-Zagajewska A, Kaczmarska M, Stefancyzk L, Nowick M. “Effect of vitamin K substition on vascular calcification and early atherosclerotic changes in patients with chronic kidney disease - preliminary results.” Nephrol Dial Transplant. 2013;28(Suppl 1):1352-57.
Ozdemir, M; Yilmaz, K; Abdulrezzak, U; Muhtaroglu, S; Patiroglu, T; Karakukcu, M; Unal, E “The Efficacy of Vitamin K2 and Calcitriol Combination on Thalassemic Osteopathy” J Pediatr Hematol Oncol. 2013 Nov;35(8):623-7
Theuwissen E, Teunissen KJ, Spronk HM, Hamulyák K, Ten Cate H, Shearer MJ, Vermeer C, Schurgers LJ. “Effect of low-dose supplements of menaquinone-7 (vitamin K2 ) on the stability of oral anticoagulant treatment: dose-response relationship in healthy volunteers.” J Thromb Haemost. 2013 Jun;11(6):1085-92
Theuwissen E, Cranenburg E, Knapen M, Magdeleyns E, Teunissen K, Schurgers L, Smit E, Vermeer C (2012). “Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects.” British Journal of Nutrition, 108, pp 1652-1657
Westenfeld, R., Krueger, T., Schlieper, G., Cranenburg, E.C., Magdeleyns, E.J., Heidenreich, S., Holzmann, S., Vermeer, C., Jahnen-Dechent, W., Ketteler, M., Floege, J., Schurgers, L.J. “Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial.” Am. J. Kidney Dis. 2012;59:186–195.
Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E. “Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.” Osteoporosis International. 2013 Sep;24(9):2499-507.
Marieke J. H. van Summeren, Lavienja A. J. L. M. Braam, Marc R. Lilien, Leon J. Schurgers, Wietse Kuis and Cees Vermeer (2009). “The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children.” British Journal of Nutrition, 102, pp 1171-1178.
Other Vitamin K2
Maresz K. “Proper Calcium Use: Vitamin K2 as a Promoter of Bone and Cardiovascular Health." Integrative Medicine: A Clinician’s Journal. 2015 Feb: 14(1).
Brandenburg, Vincent M. et al. “Prevention of vasculopathy by vitamin K supplementation: Can we turn fiction into fact?” Atherosclerosis , Volume 240 (2015), Issue 1 , 10 - 16
Juanola-Falgarona M, Salas-Salvadó J, Martínez-González MÁ, Corella D, Estruch R, Ros E, Fitó M, Arós F, Gómez-Gracia E, Fiol M, Lapetra J, Basora J, Lamuela-Raventós RM, Serra-Majem L, Pintó X, Muñoz MÁ, Ruiz-Gutiérrez V, Fernández-Ballart J, Bulló M. “Dietary intake of vitamin K is inversely associated with mortality risk.” Journal of Nutrition. 2014 May;144(5):743-50.
Beulens JW, Booth SL, van den Heuvel EG, Stoecklin E, Baka A, Vermeer C. (2013). “The role of menaquinones (vitamin K2) in human health.” British Journal of Nutrition, 110, pp 1357-1368.
Flore R, Ponziani FR, Di Rienzo TA, Zocco MA, Flex A, Gerardino L, Lupascu A, Santoro L, Santoliquido A, Di Stasio E, Chierici E, Lanti A, Tondi P, Gasbarrini A. “Something more to say about calcium homeostasis: the role of vitamin K2 in vascular calcification and osteoporosis.” European Review for Medical and Pharmacological Science. 2013 Sep;17(18):2433-40.
Cranenburg EC, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Westerhuis R, Magdeleyns EJ, Herfs M, Vermeer C, Laverman GD. “Vitamin K intake and status are low in hemodialysis patients.” Kidney International. 2012 Sep;82(5):605-10.
Sato, Toshiro, Leon J Schurgers, and Kazuhiro Uenishi. “Comparison of Menaquinone-4 and Menaquinone-7 Bioavailability in Healthy Women.” Nutrition Journal 11 (2012): 93.
Rees K, Guraewal S, Wong YL, Majanbu DL, Mavrodaris A, Stranges S, Kandala NB, Clarke A, Franco OH. “Is vitamin K consumption associated with cardio-metabolic disorders? A systematic review.” Maturitas. 2010 Oct;67(2):121-8.
Gast GC, de Roos NM, Sluijs I, Bots ML, Beulens JW, Geleijnse JM, Witteman JC, Grobbee DE, Peeters PH, van der Schouw YT. “A high menaquinone intake reduces the incidence of coronary heart disease.” Nutrition, Metabolism and Cardiovascular Diseases. 2009 Sep;19(7):504-10.
Beulens JW, Bots ML, Atsma F, Bartelink ML, Prokop M, Geleijnse JM, Witteman JC, Grobbee DE, van der Schouw YT. “High dietary menaquinone intake is associated with reduced coronary calcification.” Atherosclerosis. 2009 Apr;203(2):489-93.
Marieke J. H. van Summeren, Lavienja A. J. L. M. Braam, Marc R. Lilien, Leon J. Schurgers, Wietse Kuis and Cees Vermeer (2009). “The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children.” British Journal of Nutrition, 102, pp 1171-1178.
Nimptsch K, Rohrmann S, Linseisen J. "Dietary intake of vitamin K and risk of prostate cancer in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg)." American Journal of Clinical Nutrition. April 2008, Volume 87, Number 4, Pages 985-992.
Knapen MH, Schurgers LJ, Vermeer C.”Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women.” Osteoporos Int. 2007 ;18(7):963-72.
Schurgers LJ, Teunissen KJ, Hamulyák K, Knapen MH, Vik H, Vermeer C. “Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7.” Blood. 2007;109(8):3279-83.
Shaw LJ, Raggi P, Berman DS, Callister TQ. “Coronary artery calcium as a measure of biologic age.” Atherosclerosis. 2006;188(1):112-9
Ikeda Y, Iki M, Morita A, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H. “Intake of fermented soybeans, natto, is associated with reduced bone loss in postmenopausal women: Japanese Population-Based Osteoporosis (JPOS) Study.” J Nutr. 2006;136(5):1323-8.
Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, Hofman A, Witteman JC. “Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study.” J Nutr. 2004;134(11):3100-5.
Ushiroyama T, Ikeda A, Ueki M. “Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women.” Maturitas. 2002 Mar 25;41(3):211-21.
Schurgers LJ, Dissel PE, Spronk HM, Soute BA, Dhore CR, Cleutjens JP, Vermeer C. “Role of vitamin K and vitamin K-dependent proteins in vascular calcification.” Z Kardiol. 2001;90 Suppl 3:57-63.
Shiraki M, Shiraki Y, Aoki C, Miura M. “Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis.” Journal of Bone and Mineral Research. 2000 Mar;15(3):515-21.
Nalini P, et al. “Evaluation of analgesic activity of standardized aqueous extract of Withania somnifera in healthy human volunteers using mechanical pain model.” Submitted for publication.
Rani PU, et al. “Evaluation of effect of Withania somnifera (Sensoril®) on cold pressor test induced cardiovascular changes in healthy human subjects.” Submitted for publication.
Pingali U, Fatima N, Kumar C, Kishan P. 2014. “Evaluation of a highly standardized Withania somnifera extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: A randomized, double blind, placebo controlled study.” International Journal of Ayurveda and Pharma Research. 2014, May;2(3):22-32.
Pingali U, Pilli R, Fatima N. “Effect of standardized aqueous extract of Withania somniferaon tests of cognitive and psychomotor performance in healthy human participants.” Pharmacognosy Research. 2014 Jan;6(1):12-8.
Chengappa KN, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R. “Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder.” Journal of Clinical Psychiatry. 2013 Nov;74(11):1076-83.
Nalini P, Usharani P, Manjunath K, SunilKumarReddy K. “Evaluation of the analgesic activity of standardized aqueous extract of Withania somnifera in healthy human volunteers using Hot Air Pain Model.” Res J Life Sci.2013
Pingali U, Pilli R, Fatima N. “Effect of Withania somnifera extract on mental stress induced changes in hemodynamic properties and arterial wave reflections in healthy subjects.” Current Topics in Nutraceutical Research. 2013 11(4):151-158.
Kalani A, Bahtiyar G, Sacerdote A. “Ashwagandha root in the treatment of non-classical adrenal hyperplasia.” BMJ Case Rep. 2012 Sep 17;2012. pii: bcr2012006989.
Auddy B, Hazra J, Mitra A, Abedon B, Ghosal S. “A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans: A Double-blind Randomized, Placebo-Controlled Study.” JANA. Vol II, No. I, 2008.
Chandrasekhar K, Kapoor J, Anishetty S. “A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults.” Indian J Psychol Med 2012;34:255-62
Sharma, V., Sharma, S., Pracheta., Paliwal, R., “W.somnifera rejuvenating ayurvedic medicinal herb for the treatment of various human ailments.” Int J of PharmTech Research. 2011 3(1): 187-192.
Mishra LC, Singh BB, Dagenais S. “Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review.” Alternative Medicine Review. 2000 Aug;5(4):334-46.
Aydın H, Deyneli O, Yavuz D, Gözü H, Mutlu N, Kaygusuz, Akalın S.. “Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women.” Biological Trace Element Research. 2010 Feb;133(2):136-43.
Champagne CM. “Magnesium in hypertension, cardiovascular disease, metabolic syndrome, and other conditions: a review.” Nutrition in Clinical Practice. 2008 Apr-May;23(2):142-51.
Mutlu M, Argun M, Kilic E, Saraymen R, Yazar S. “Magnesium, zinc and copper status in osteoporotic, osteopenic and normal post-menopausal women.” Journal of International Medical Research. 2007 Sep-Oct;35(5):692-5.
Carpenter TO, DeLucia MC, Zhang JH, Bejnerowicz G, Tartamella L, Dziura J, Petersen KF, Befroy D, Cohen D. “A randomized controlled study of effects of dietary magnesium oxide supplementation on bone mineral content in healthy girls.” The Journal of Clinical Endocrinology and Metabolism. 2006 Dec;91(12):4866-72.
Ryder M, Shorr R,. Bush A, Kritchevsky S, Harris T, Stone K, Cauley J, Tylavsky F. “Magnesium Intake from Food and Supplements Is Associated with Bone Mineral Density in Healthy Older White Subjects.” Journal of the American Geriatrics Society. November 2005:Volume 53, Issue 11, pages 1875–1880.
Palacios C. “The Role of Nutrients in Bone Health, from A to Z.” Critical Reviews in Food Science and Nutrition. 2006:Volume 46, Issue 8.
New, Susan A., et al. "Dietary influences on bone mass and bone metabolism: further evidence of a positive link between fruit and vegetable consumption and bone health?." The American Journal of Clinical Nutrition. 2000 Jan;71(1):142-51.
Tucker KL, Hannan MT, Chen H, Cupples LA, Wilson PW, Kiel DP. “Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women.” American Journal of Clinical Nutrition. 1999 Apr;69(4):727-36.
Sojka J. “Magnesium Supplementation and Osteoporosis.” Nutrition Reviews. 1995 Mar:53.3: 71-74.
Meacham S, Taper L, Volpe S. “Effects of boron supplementation on bone mineral density and dietary, blood, and urinary calcium, phosphorus, magnesium, and boron in female athletes.” Environmental Health Perspectives. 1994 Nov; 102(Suppl 7): 79–82.
Newnham RE. “Essentiality of boron for healthy bones and joints.” Environmental Health Perspectives. 1994 Nov;102 Suppl 7:83-5.
Beattie JH, Peace HS. “The influence of a low-boron diet and boron supplementation on bone, major mineral and sex steroid metabolism in postmenopausal women.” British Journal of Nutrition. 993 May;69(3):871-84.
Travers R, Rennie G, Newnham R. “Boron and Arthritis: The Results of a Double-blind Pilot Study.”Jounral of Nutritional and Environmental Medicine. 1990, Vol. 1, No. 2 , Pages 127-132.